02105 來凱醫藥－Ｂ
按盘价 
15.000 +0.210 (+1.420%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -19.312% | -26.876% | -52.234% | -166.525% | -163.228% |
| 股东资金回报率 (%) | -23.103% | -31.614% | N/A | N/A | 67.403% |
| 资本运用回报率 (%) | -19.348% | -31.334% | -45.390% | -204.416% | -179.670% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 80.978% | N/A | N/A | N/A | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -236.724% | N/A | N/A | N/A | N/A |
| 税前边际利润率 (%) | -214.880% | N/A | N/A | N/A | N/A |
| 纯利率 (%) | -214.880% | N/A | N/A | N/A | N/A |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 5.543 X | 5.478 X | 6.580 X | 3.432 X | 7.356 X |
| 速动比率 (X) | 5.543 X | 5.478 X | 6.580 X | 3.432 X | 7.356 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 16.572% | 16.171% | 13.765% | 497.005% | 342.167% |
| 总债项 / 总资产比率 (%) | 8.541% | 10.867% | 6.048% | 5.898% | 6.068% |
| 净债项 / 总资产比率 (%) | -79.330% | -55.424% | -41.234% | -61.428% | -58.532% |
| 总债项 / 股东资金比率 (%) | 10.238% | 12.963% | 7.013% | N/A | N/A |
| 长期债项 / 股东资金比率 (%) | 0.118% | 0.407% | 0.630% | N/A | N/A |
| 净债项 / 股东资金比率 (%) | -95.088% | -66.116% | -47.816% | N/A | N/A |
| 净现金 / (债项) ($) | 11.22亿 | 5.32亿 | 3.84亿 | 2.95亿 | 2.69亿 |
| 每股净现金 / (债项) ($) | 2.514 | 1.305 | 0.985 | -- | -- |
| 总债项 / 资本运用比率 (%) | 10.195% | 12.855% | 6.939% | 7.402% | 6.679% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 备注： | 实时报价更新时间为20/03/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -229,318 |
| 增长率 | -9.822% |
| 每股盈利/(亏损) | RMB -0.590 |
| 每股账面资产净值 (¥) | RMB 2.644 |